# EDGAR Filing Document

**Accession Number:** 0001877184
**File Stem:** 0001193125-26-111339
**Filing Date:** 2026-3
**Character Count:** 34846
**Document Hash:** aa8eedd8dfbae2d6897333ae8484257e
**Contains OCR:** False
**Source Format:** 

## Filing Content

## Filing Summary
**0001193125-26-111339.hdr.sgml**: 20260318

**ACCESSION NUMBER**: 0001193125-26-111339

**CONFORMED SUBMISSION TYPE**: S-8

**PUBLIC DOCUMENT COUNT**: 13

**FILED AS OF DATE**: 20260318

**DATE AS OF CHANGE**: 20260317

**EFFECTIVENESS DATE**: 20260318

**FILER**: 

**COMPANY DATA:**
- **COMPANY CONFORMED NAME:** KESTRA MEDICAL TECHNOLOGIES, LTD.
- **CENTRAL INDEX KEY:** 0001877184
- **STANDARD INDUSTRIAL CLASSIFICATION:** SURGICAL & MEDICAL INSTRUMENTS & APPARATUS [3841]
- **ORGANIZATION NAME:** 08 Industrial Applications and Services
- **EIN:** 000000000
- **STATE OF INCORPORATION:** D0
- **FISCAL YEAR END:** 0430

**FILING VALUES:**
- **FORM TYPE:** S-8
- **SEC ACT:** 1933 Act
- **SEC FILE NUMBER:** 333-294390
- **FILM NUMBER:** 26763912

**BUSINESS ADDRESS:**
- **STREET 1:** 3933 LAKE WASHINGTON BLVD NE
- **STREET 2:** SUITE 200
- **CITY:** KIRKLAND
- **STATE:** WA
- **ZIP:** 98033
- **BUSINESS PHONE:** (425) 279-8002

**MAIL ADDRESS:**
- **STREET 1:** 3933 LAKE WASHINGTON BLVD NE
- **STREET 2:** SUITE 200
- **CITY:** KIRKLAND
- **STATE:** WA
- **ZIP:** 98033

**As filed with the Securities and Exchange Commission on March 17, 2026** 

**Registration No. 333-______** 

**UNITED STATES** 

**SECURITIES AND EXCHANGE COMMISSION** 

**Washington, D.C. 20549** 

**FORM S-8** 

**REGISTRATION STATEMENT** 

***UNDER***

***THE SECURITIES ACT OF 1933***

## Kestra Medical Technologies, Ltd.
**(Exact name of registrant as specified in its charter)** 

---

| | |
|:---|:---|
| **Bermuda** | **Not Applicable** |
| **(State or other jurisdiction of**<br> **incorporation or organization)** | **(I.R.S. Employer**<br> **Identification No.)** |
| **3933 Lake Washington Blvd NE, Suite 200**<br> **Kirkland, Washington** | **98033** |
| **(Address of Principal Executive Offices)** | **(Zip Code)** |

---

**Kestra Medical Technologies, Ltd. 2025 Employee Stock Purchase Plan** 

**(Full title of the plan)** 

**Brian Webster** 

**Chief Executive Officer** 

**3933 Lake Washington Blvd NE, Suite 200** 

**Kirkland, Washington 98033** 

**(Name and address of agent for service)** 

**(425) 279-8002**

**(Telephone number, including area code, of agent for service)** 

***Copies to:***

---

| | |
|:---|:---|
| **Sophia Hudson, P.C.**<br> **Christie W.S. Mok**<br> **Kirkland & Ellis LLP**<br> **601 Lexington Avenue**<br> **New York, New York 10022**<br> **Telephone: (212) 446-4800** | **Traci S. Umberger**<br> **General Counsel and**<br> **Chief Administrative Officer**<br> **3933 Lake Washington Blvd NE, Suite 200**<br> **Kirkland, Washington 98033**<br> **Telephone: (425) 279-8002** |

---

Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, a smaller reporting company or an emerging growth company. See the definitions of "large accelerated filer," "accelerated filer," "smaller reporting company," and "emerging growth company" in Rule 12b-2 of the Exchange Act.

---

| | | | |
|:---|:---|:---|:---|
| Large accelerated filer | ☐ | Accelerated filer | ☐ |
| Non-accelerated filer | ☒ | Smaller reporting company | ☒ |
|  |  | Emerging growth company | ☒ |

---

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 7(a)(2)(B) of the Securities Act. ☐

**Explanatory Note** 

Kestra Medical Technologies, Ltd. (the "Registrant") is filing this Registration Statement on Form S-8 (this "Registration Statement") with the Securities and Exchange Commission (the "Commission") to register 1,083,209 common shares reserved for issuance under the Kestra Medical Technologies, Ltd. 2025 Employee Stock Purchase Plan (the "ESPP"). This Registration Statement is being filed in order to register common shares which may be offered or sold to participants under the ESPP.

------

**PART I** 

**INFORMATION REQUIRED IN THE SECTION 10(a) PROSPECTUS** 

**Item 1. Plan Information.** 

The documents containing the information specified in Part I will be delivered in accordance with Rule 428(b) under the Securities Act of 1933, as amended (the "Securities Act"). Such documents are not required to be, and are not being, filed with the Commission, either as part of this Registration Statement or as prospectuses or prospectus supplements pursuant to Rule 424 under the Securities Act. These documents, and the documents incorporated by reference in this Registration Statement pursuant to Item 3 of Part II of the Form S-8, taken together, constitute a prospectus that meets the requirements of Section 10(a) of the Securities Act.

**Item 2. Registrant Information and Employee Plan Annual Information.** 

The written statement required by Item 2 of Part I is included in documents that will be delivered to participants in the plans covered by this Registration Statement pursuant to Rule 428(b) of the Securities Act.

------

**PART II** 

**INFORMATION REQUIRED IN THE REGISTRATION STATEMENT** 

**Item 3. Incorporation of Documents by Reference.** 

The following documents, which have been filed by the Registrant with the Commission, are incorporated in this Registration Statement by reference:

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(a) The Registrant's Annual Report on [Form 10-K](http://www.sec.gov/Archives/edgar/data/../../../ix?doc=/Archives/edgar/data/0001877184/000095017025096609/ck0001877184-20250430.htm) for the fiscal year ended April 30, 2025, filed with the Commission on July 17, 2025 (the "2025 Annual Report");

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(b) The Registrant's Quarterly Reports on Form 10-Q for the quarterly periods ended July 31, 2025, October 31, 2025 and January 31, 2026, filed with the Commission on [September 12, 2025](http://www.sec.gov/Archives/edgar/data/../../../ix?doc=/Archives/edgar/data/0001877184/000095017025114536/ck0001877184-20250731.htm), [December 11, 2025](http://www.sec.gov/Archives/edgar/data/../../../ix?doc=/Archives/edgar/data/0001877184/000119312525316210/ck0001877184-20251031.htm) and [March 17, 2026](http://www.sec.gov/Archives/edgar/data/../../../ix?doc=/Archives/edgar/data/1877184/000119312526111205/ck0001877184-20260131.htm), respectively

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(c) The information specifically incorporated by reference into the 2025 Annual Report from its Definitive Proxy Statement on[Schedule 14A](http://www.sec.gov/Archives/edgar/data/1877184/000119312525162541/d78457ddef14a.htm) filed on July 22, 2025;

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(d) The Registrant's Current Reports on Form 8-K, filed with the Commission on [June 6, 2025](http://www.sec.gov/Archives/edgar/data/../../../ix?doc=/Archives/edgar/data/0001877184/000119312525136269/d926981d8k.htm), [September 4, 2025](http://www.sec.gov/Archives/edgar/data/../../../ix?doc=/Archives/edgar/data/0001877184/000095017025113058/ck0001877184-20250903.htm) and [December 4, 2025](http://www.sec.gov/Archives/edgar/data/../../../ix?doc=/Archives/edgar/data/0001877184/000119312525308144/d92377d8k.htm); and

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(e) The description of the Registrant's common shares, contained in [Exhibit 4.4](http://www.sec.gov/Archives/edgar/data/1877184/000095017025096609/ck0001877184-ex4_4.htm) to the 2025 Annual Report, including any amendments or reports filed for the purpose of updating such description.

All documents subsequently filed by the Registrant pursuant to Sections 13(a), 13(c), 14 and 15(d) of the Exchange Act after the date of this Registration Statement, but prior to the filing of a post-effective amendment that indicates that all securities offered hereby have been sold or that deregisters all securities then remaining unsold shall be deemed to be incorporated by reference herein and to be a part hereof from the date of filing of such documents.

Any statement contained in a document incorporated or deemed to be incorporated by reference herein shall be deemed to be modified or superseded for purposes of this Registration Statement to the extent that a statement contained herein or in any other subsequently filed document which also is incorporated or deemed to be incorporated by reference herein modifies or supersedes such statement. Any statement so modified or superseded shall not be deemed, except as so modified or superseded, to constitute a part of this Registration Statement.

**Item 4. Description of Securities.** 

Not applicable.

**Item 5. Interests of Named Experts and Counsel.** 

Not applicable.

**Item 6. Indemnification of Directors and Officers.** 

Section 98 of the Companies Act 1981, as amended, of Bermuda (the "Companies Act") provides generally that a Bermuda company may indemnify its directors, officers and auditors against any liability which by virtue of any rule of law would otherwise be imposed on them in respect of any negligence, default, breach of duty or breach of trust, except in cases where such liability arises from fraud or dishonesty of which such director, officer or auditor may be guilty in relation to the company. Section 98 of the Companies Act further provides that a Bermuda company may indemnify its directors, officers and auditors against any liability incurred by them in defending any proceedings, whether civil or criminal, in which judgment is awarded in their favor or in which they are acquitted or granted relief by the Supreme Court of Bermuda pursuant to Section 281 of the Companies Act.

------

The Registrant's amended and restated bye-laws (the "Bye-Laws") provide that the Registrant shall indemnify its directors and any officers appointed by the Registrant's Board of Directors to the fullest extent permitted by the Companies Act; provided, however, that if a director or officer is a party to an indemnification agreement with the Registrant, then the terms of the indemnification agreement shall apply instead of the provision in the Bye-Laws. The Bye-Laws also provide that the shareholders waive any claims or rights of action that they might have, individually or in right of the Registrant, against any of the Registrant's directors or officers for any act or failure to act in the performance of such director's or officer's duties, except in respect of any fraud or dishonesty of such director or officer or any claims of violations of the Securities Act or the Exchange Act. Section 98A of the Companies Act permits the Registrant to purchase and maintain insurance for the benefit of any officer or director in respect of any loss or liability attaching to him or her in respect of any negligence, default, breach of duty or breach of trust, whether or not the Registrant may otherwise indemnify such officer or director. The Registrant has purchased and maintains a directors' and officers' liability policy for such purpose.

Insofar as indemnification for liabilities arising under the Securities Act may be permitted to directors, officers and controlling persons of the Registrant pursuant to the foregoing provisions, or otherwise, the Registrant has been advised that in the opinion of the Commission such indemnification is against public policy as expressed in the Securities Act and is therefore unenforceable.

In addition, the Registrant has entered into indemnification agreements with each of its directors and executive officers and certain additional officers. These indemnification agreements provide the directors and officers with contractual rights to indemnification to the fullest extent permitted by the Companies Act, subject to certain exceptions and procedures. The indemnification agreements may require the Registrant, among other things, to indemnify such persons against expenses, including attorneys' fees, judgments, liabilities, fines and settlement amounts incurred by any such person in actions or proceedings, including actions by the Registrant or in the Registrant's right, that may arise by reason of their status or service as a director or officer, and to advance expenses incurred by them in connection with any such proceedings. The form of such indemnification agreement was filed as Exhibit 10.5 to the 2025 Annual Report.

**Item 7. Exemption from Registration Claimed.** 

Not applicable.

------

**Item 8. Exhibits.** 

---

| | |
|:---|:---|
| **Exhibit<br>Number** | **Description of Exhibit** |
| 4.1 | [Certificate of Incorporation (incorporated by reference to Exhibit 3.1 to the 2025 Annual Report)\*\*](http://www.sec.gov/Archives/edgar/data/1877184/000119312525023649/d744414dex31.htm) |
| 4.2 | [Memorandum of Association (incorporated by reference to Exhibit 3.2 to the 2025 Annual Report)\*\*](http://www.sec.gov/Archives/edgar/data/1877184/000119312525023649/d744414dex32.htm) |
| 4.3 | [Amended and Restated Bye-Laws of the Registrant (incorporated by reference to Exhibit 3.3 to the 2025 Annual Report)\*\*](http://www.sec.gov/Archives/edgar/data/1877184/000119312525049896/d890644dex31.htm) |
| 4.4 | [Certificate of Deposit of Memorandum of Increase of Share Capital (incorporated by reference to Exhibit 3.4 to the 2025 Annual Report)\*\*](http://www.sec.gov/Archives/edgar/data/1877184/000119312525049896/d890644dex32.htm) |
| 4.5 | [Kestra Medical Technologies, Ltd. 2025 Employee Stock Purchase Plan (incorporated by reference to Exhibit 10.1 to the Registrant's Quarterly Report on Form 10-Q for the quarterly period ended January 31, 2026 filed with the Commission on March 17, 2026)\*\*](http://www.sec.gov/Archives/edgar/data/1877184/000119312526111205/ck0001877184-ex10_1.htm) |
| 5.1 | [Opinion of Walkers (Bermuda) Limited, Bermuda Counsel to the Registrant](d105899dex51.htm) |
| 23.1 | [Consent of PricewaterhouseCoopers LLP, Independent Registered Public Accounting Firm, of Kestra Medical Technologies, Ltd.](d105899dex231.htm) |
| 23.2 | [Consent of Walkers (Bermuda) Limited (included as part of Exhibit 5.1)](d105899dex51.htm) |
| 24.1 | [Power of Attorney (included in signature page)](#sig) |
| 107 | [Filing Fee Table](d105899dexfilingfees.htm) |

---

**\*\*** Previously filed. 

------

**Item 9. Undertakings.** 

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(a) The Registrant hereby undertakes:

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(1) To file, during any period in which offers or sales are being made, a post-effective amendment to this Registration Statement:

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(i) To include any prospectus required by Section 10(a)(3) of the Securities Act;

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(ii) To reflect in the prospectus any facts or events arising after the effective date of the registration statement (or the most recent post-effective amendment thereof) which, individually or in the aggregate, represent a fundamental change in the information set forth in this Registration Statement; and

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(iii) To include any material information with respect to the plan of distribution not previously disclosed in this Registration Statement or any material change to such information in this Registration Statement;

*provided, however,* that subparagraphs (a)(1)(i) and (a)(1)(ii) do not apply if the information required to be included in a post-effective amendment by those paragraphs is contained in reports filed with or furnished to the Commission by the Registrant pursuant to Section 13 or Section 15(d) of the Securities Exchange Act of 1934 that are incorporated by reference in this Registration Statement.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(2) That, for the purpose of determining any liability under the Securities Act, each such post-effective amendment shall be deemed to be a new registration statement relating to the securities offered therein, and the offering of such securities at that time shall be deemed to be the initial bona fide offering thereof.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(3) To remove from registration by means of a post-effective amendment any of the securities being registered which remain unsold at the termination of the offering.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(b) The undersigned Registrant hereby undertakes that, for the purposes of determining any liability under the Securities Act, each filing of the Registrant's annual report pursuant to Section 13(a) or Section 15(d) of the Securities Exchange Act of 1934 (and, where applicable, each filing of an employee benefit plan's annual report pursuant to Section 15(d) of the Securities Exchange Act of 1934) that is incorporated by reference in this Registration Statement shall be deemed to be a new registration statement relating to the securities offered therein, and the offering of such securities at that time shall be deemed to be the initial bona fide offering thereof.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(c) Insofar as indemnification for liabilities arising under the Securities Act may be permitted to directors, officers and controlling persons of the registrant pursuant to the foregoing provisions, or otherwise, the Registrant has been advised that in the opinion of the Commission such indemnification is against public policy as expressed in the Securities Act and is, therefore, unenforceable. In the event that a claim for indemnification against such liabilities (other than the payment by the registrant of expenses incurred or paid by a director, officer or controlling person of the registrant in the successful defense of any action, suit or proceeding) is asserted by such director, officer or controlling person in connection with the securities being registered, the Registrant will, unless in the opinion of its counsel the matter has been settled by controlling precedent, submit to a court of appropriate jurisdiction the question whether such indemnification by it is against public policy as expressed in the Securities Act and will be governed by the final adjudication of such issue.

------

**SIGNATURES** 

Pursuant to the requirements of the Securities Act of 1933, the registrant certifies that it has reasonable grounds to believe that it meets all of the requirements for filing on Form S-8 and has duly caused this Registration Statement to be signed on its behalf by the undersigned, thereunto duly authorized, in the City of Kirkland, State of Washington, on March 17, 2026.

---

| | |
|:---|:---|
| **KESTRA MEDICAL TECHNOLOGIES, LTD.** | **KESTRA MEDICAL TECHNOLOGIES, LTD.** |
| By: | /s/ Brian Webster |
| Name: | Brian Webster |
| Title: | President and Chief Executive Officer |

---

KNOW ALL PERSONS BY THESE PRESENTS, that each person whose signature appears below hereby constitutes and appoints Brian Webster and Traci S. Umberger and each of them, individually, as his or her true and lawful attorneys-in-fact and agents, with full power of substitution and resubstitution, for him or her and in his or her name, place and stead in any and all capacities, in connection with this Registration Statement, including to sign in the name and on behalf of the undersigned, this Registration Statement and any and all amendments thereto, including post-effective amendments and registrations filed pursuant to Rule 462 under the U.S. Securities Act of 1933, and to file the same, with all exhibits thereto, and other documents in connection therewith, with the U.S. Securities and Exchange Commission, granting unto such attorneys-in-fact and agents full power and authority to do and perform each and every act and thing requisite and necessary to be done in and about the premises, as fully to all intents and purposes as he might or could do in person, hereby ratifying and confirming all that said attorneys-in-fact and agents, or his or her substitute, may lawfully do or cause to be done by virtue hereof.

------

Pursuant to the requirements of the Securities Act of 1933, this Registration Statement has been signed by the following persons in the capacities and on the dates indicated.

---

| | | |
|:---|:---|:---|
| **Signature** | **Title** | **Date** |
| /s/ Brian Webster<br> Brian Webster | President, Chief Executive Officer and Director<br> (Principal Executive Officer) | March 17, 2026 |
| /s/ Vaseem Mahboob<br> Vaseem Mahboob | Chief Financial Officer<br> (Principal Financial and Accounting Officer) | March 17, 2026 |
| /s/ Traci S. Umberger<br> Traci S. Umberger | General Counsel, Chief<br> Administrative Officer and Director | March 17, 2026 |
| /s/ Jeffrey Schwartz<br> Jeffrey Schwartz | Director | March 17, 2026 |
| /s/ Raymond W. Cohen<br> Raymond W. Cohen | Director | March 17, 2026 |
| /s/ Conor Hanley<br> Conor Hanley | Director | March 17, 2026 |
| /s/ Elizabeth Kwo, Ph.D.<br> Elizabeth Kwo, Ph.D. | Director | March 17, 2026 |
| /s/ Mary Kay Ladone<br> Mary Kay Ladone | Director | March 17, 2026 |
| /s/ Kevin Reilly<br> Kevin Reilly | Director | March 17, 2026 |

---

------

**AUTHORIZED REPRESENTATIVE** 

Pursuant to the requirements of Section 6(a) of the Securities Act of 1933, the undersigned has signed this Registration Statement, solely in its capacity as the duly authorized representative of Kestra Medical Technologies, Ltd., in Kirkland, Washington, on March 17, 2026.

---

| | |
|:---|:---|
| **KESTRA MEDICAL TECHNOLOGIES, LTD.** | **KESTRA MEDICAL TECHNOLOGIES, LTD.** |
| By: | /s/ Brian Webster |
| Name: | Brian Webster |
| Title: | President and Chief Executive Officer |

---

## Exhibit 5.1

---

| | |
|:---|:---|
|  | **Exhibit 5.1** |
| 17 March 2026 | Our Ref: RN//MS/dss/W3229-A04905 |
| Kestra Medical Technologies, Ltd.<br> Cumberland House, 7th Floor<br> 1 Victoria Street<br> Hamilton, HM11<br> Bermuda |  |

---

Dear Addressees

**KESTRA MEDICAL TECHNOLOGIES, LTD. (THE "COMPANY")** 

We have been asked to provide this legal opinion to you with regard to the laws of Bermuda in connection with a registration statement on form S-8 filed with the U.S. Securities and Exchange Commission (the "**Commission**") on March 17, 2026 (the "**Registration Statement**") relating to the registration under the U.S. Securities Act of 1933 (as amended) (the "**Securities Act**") of 1,083,209 common shares, par value US$1.00 per share (the "**Common Shares**"), issuable pursuant to the Plan (as defined in Schedule 1) of the Company.

For the purposes of giving this opinion, we have examined and relied upon the originals or copies of the documents listed in Schedule 1 (the "**Documents**").

In giving this opinion we have relied upon the assumptions set out in Schedule 2, which we have not independently verified.

We are Bermuda Barristers and Attorneys and express no opinion as to any laws other than the laws of Bermuda in force and as interpreted at the date of this opinion. We have not, for the purposes of this opinion, made any investigation of the laws, rules or regulations of any other jurisdiction.

Based upon the foregoing examinations and the assumptions and qualifications set out below and upon such searches as we have conducted and having regard to legal considerations which we consider relevant, and subject to the qualifications set out in Schedule 3, and under the laws of Bermuda, we are of the opinion the Common Shares will upon payment and delivery as contemplated by the Registration Statement and Plan and any relevant agreements duly authorised by and in accordance with the Plan, be duly authorised and validly issued, fully paid and non-assessable.

This opinion is limited to the matters referred to herein and shall not be construed as extending to any other matter or document not referred to herein. This opinion is given solely for your benefit and the benefit of your legal advisers acting in that capacity in relation to this transaction and may not be relied upon by any other person, other than persons entitled to rely upon it pursuant to the provisions of the Securities Act, without our prior written consent.

This opinion shall be construed in accordance with the laws of Bermuda.

We hereby consent to the filing of this opinion as an exhibit to the Registration Statement.

---

| |
|:---|
| Yours faithfully |
| */s/ Walkers (Bermuda) Limited* |
| **WALKERS (BERMUDA) LIMITED** |

---

------

**WALKERS**

**SCHEDULE 1** 

**LIST OF DOCUMENTS EXAMINED** 

1. The Certificate of Incorporation dated 20 May 2021, the Memorandum of Association as registered on
20 May 2021, the Amended and Restated Bye-laws of the Company as adopted on 7 March 2025 (together the "**Memorandum and Bye-laws** "), Register
of Members, Register of Directors and Officers and the Certificate of Deposit of Memorandum of Increase of Share Capital in each case of the Company, copies of which have been provided to us by the Company's secretary, being Maples Corporate
Services (Bermuda) Limited (together, the "**Company Records** ").

2. A copy of the executed unanimous written resolutions of the board of directors of the Company dated 4 June 2025
and a copy of the minutes and resolutions of the annual general meeting of the shareholders of the Company which took place on 3 September 2025 (together, the "**Resolutions** ").

3. A copy of the final form of the Registration Statement on Form S-8, which incorporates the following documents:

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(a) The Company's Annual Report on Form 10-K for the fiscal year
ended April 30, 2025, filed with the Securities and Exchange Commission (the "Commission") on July 17, 2025 (the "**2025 Annual Report** ");

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(b) The Company's Quarterly Reports on Form 10-Q for the quarterly
periods ended July 31, 2025, October 31, 2025 and January 31, 2026, filed with the Commission on September 12, 2025, December 11, 2025 and March 17, 2026, respectively;

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(c) The information specifically incorporated by reference into the 2025 Annual Report from its Definitive Proxy
Statement on [Schedule 14A](http://www.sec.gov/Archives/edgar/data/1877184/000119312525162541/d78457ddef14a.htm) filed on July 22, 2025;

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(d) The Company's Current Reports on Form 8-K, filed with the
Commission on June 6, 2025, September 4, 2025 and December 4, 2025; and

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(e) The description of the Company's common shares, contained in Exhibit 4.4 to the 2025 Annual Report,
including any amendments or reports filed for the purpose of updating such description.

4. A copy of the Kestra Medical Technologies, Ltd. 2025 Employee Stock Purchase Plan (the
" **Plan** ").

------

**WALKERS** 

**SCHEDULE 2** 

**ASSUMPTIONS** 

1. There are no provisions of the laws of any jurisdiction outside Bermuda which would be contravened by the
execution or delivery of the Documents or in any contracts or instruments, including but not limited to indentures and instruments, prepared in relation to the offer and creation of any of the Common Shares, as contemplated by the Registration
Statement and, insofar as any obligation expressed to be incurred under the Registration Statement is to be performed in or is otherwise subject to the laws of any jurisdiction outside Bermuda, its performance will not be illegal by virtue of the
laws of that jurisdiction.

2. The Plan constitutes or, when executed and delivered, will constitute the legal, valid and binding obligations
of each of the parties thereto enforceable in accordance with its terms as a matter of the laws of all relevant jurisdictions (other than Bermuda).

3. The choice of the laws of the jurisdiction selected to govern the Plan has been made in good faith and will be
regarded as a valid and binding selection which will be upheld in the courts of that jurisdiction and all relevant jurisdictions (other than Bermuda).

4. All authorisations, approvals, consents, licences and exemptions required by, and all filings and other steps
required of each of the parties to the Registration Statement and the Plan outside Bermuda to ensure the legality, validity and enforceability of the Registration Statement and the Plan have been or will be duly obtained, made or fulfilled and are
and will remain in full force and effect and any conditions to which they are subject have been satisfied.

5. The originals of all documents examined in connection with this opinion are authentic. The signatures, initials
and seals on the Documents are genuine and are those of a person or persons given power to execute the Documents under the Resolutions or any power of attorney given by the Company to execute the Documents. All documents purporting to be sealed have
been so sealed. All copies are complete and conform to their originals. Any translations are a true translation of the original document they purport to translate. The Documents conform in every material respect to the latest drafts of the same
produced to us.

6. The Memorandum and Bye-laws reviewed by us are the memorandum of
association and bye-laws of the Company in force at the date hereof.

7. The Company Records are complete and accurate and all matters required by law and the Memorandum and Bye-laws of the Company to be recorded therein are so recorded.

8. The Resolutions have been duly executed by or on behalf of each director or shareholder, as applicable, of the
Company and the signatures and initials thereon are those of a person or persons in whose name the Resolutions have been expressed to be signed.

9. There is no provision of any award agreement granted pursuant to the Plan which would have any implication in
relation to the opinions expressed herein.

------

**WALKERS** 

**SCHEDULE 3** 

**QUALIFICATIONS** 

1. We express no opinion upon any provisions in the Documents which contain a reference to any law or statute that
is not a Bermudian law or statute.

2. We express no opinion with respect to the issue of the Common Shares pursuant to any provision of the Plan that
purports to obligate the Company to issue such Common Shares following the commencement of a winding up of the Company.

3. Except as explicitly stated in this opinion, we express no opinion in relation to any representation or
warranty contained in the Documents nor upon matters of fact or the commercial terms of the transactions contemplated by the Documents.

4. "Non-assessability" is not a legal concept under Bermuda law. Reference in this opinion to shares
being "non-assessable" shall mean, in relation to fully-paid shares of the Company and subject to any contrary provision in any agreement in writing between the Company and the holder of shares,
that no member shall be:

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(a) obliged to contribute further amounts to the capital of the Company, either in order to complete payment for
their shares, to satisfy claims of creditors of the Company, or otherwise; and

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(b) bound by an alteration of the Memorandum of Association or Bye-laws of
the Company after the date on which they became a member, if and so far as the alteration requires them to take, or subscribe for additional shares, or in any way increases their liability to contribute to the share capital of, or otherwise to pay
money to, the Company.

## Exhibit 23.1

Exhibit 23.1

CONSENT OF INDEPENDENT REGISTERED PUBLIC ACCOUNTING FIRM

We hereby consent to the incorporation by reference in this Registration Statement on Form S-8 of Kestra Medical Technologies, Ltd. (the "Registrant") of our report dated July 17, 2025, relating to the financial statements of the Registrant, which appears in the Registrant's Annual Report on Form 10-K for the fiscal year ended April 30, 2025.

---

| |
|:---|
| /s/ PricewaterhouseCoopers LLP |
|  Irvine, California |
|  March 17, 2026 |

---

## Ex-Filing

?xml version='1.0' encoding='ASCII'? EX-FILING FEES

---

| |
|:---|
| **Calculation of Filing Fee Tables**  |
| &nbsp;&nbsp;&nbsp;&nbsp;**S-8**  |
| &nbsp;&nbsp;&nbsp;&nbsp;**KESTRA MEDICAL TECHNOLOGIES, LTD.**  |

---

---

| | | | | | | | | |
|:---|:---|:---|:---|:---|:---|:---|:---|:---|
| | **Security Type**  | **Security Class Title**  | **Fee Calculation Rule**  | **Amount Registered**  | **Proposed Maximum Offering Price Per Unit**  | **Maximum Aggregate Offering Price**  | **Fee Rate**  | **Amount of Registration Fee**  |
| 1 | Equity | Common shares, $1.00 par value, issuable pursuant to the 2025 ESPP | Other | 1083209 | $17.28 | $18717851.52 | 0.0001381 | $2584.94 |
| Total Offering Amounts: | Total Offering Amounts: | Total Offering Amounts: | Total Offering Amounts: | Total Offering Amounts: |  | $18717851.52  |  | $2584.94  |
| Total Fee Offsets:  | Total Fee Offsets:  | Total Fee Offsets:  | Total Fee Offsets:  | Total Fee Offsets:  |  |  |  | $0.00  |
| Net Fee Due:  | Net Fee Due:  | Net Fee Due:  | Net Fee Due:  | Net Fee Due:  |  |  |  | $2584.94  |

---

 **Offering Note** <br>

<sup>1</sup> (1) Pursuant to Rule 416(a) under the Securities Act of 1933, as amended (the "Securities Act"), this Registration Statement on Form S-8 (the "Registration Statement") shall also cover any additional common shares, $1.00 par value (the "common shares") of Kestra Medical Technologies, Ltd. (the "Registrant") that become issuable under the Kestra Medical Technologies, Ltd. 2025 Employee Stock Purchase Plan (the "2025 ESPP") by reason of any share dividend, share split, recapitalization or other similar transaction. (2) The amount registered includes additional common shares reserved for future issuance pursuant to the annual "evergreen" provision of the 2025 ESPP, under which, on January 1st of each year from 2026 to 2035, the common shares available for issuance under the 2025 ESPP increases by the lesser of (a) 1% of the outstanding shares on the last day of the prior year or (b) a smaller number as determined by the Board of Directors of the Registrant. (3) The Proposed Maximum Offering Price Per Unit is estimated solely for the purpose of calculating the registration fee in accordance with Rule 457(h) under the Securities Act. The Proposed Maximum Offering Price Per Unit and the Maximum Aggregate Offering Price are based on the Proposed Maximum Offering Price Per Unit of $20.33 per share, representing the average of the high and low sales prices of the common shares as reported on Nasdaq on March 12, 2026, multiplied by 85%, which is the percentage of the trading price per share applicable to purchasers under the 2025 ESPP.

---

| |
|:---|
| |
| **Rule 457(p)** |
| Fee Offset Claims |
| Fee Offset Sources |

---